Search
Global
中文版 English
Search

# Hot Search #

EVOMELA CNTC19 BI-1206 CID-103
We are CASI
We are CASI

An innovative biopharmaceutical company
focused on hematologic malignancies,
oncology and other unmet medical needs

Learn More
We are CASI
We are CASI

We explore innovative therapies to
save patients' lives

Learn More
About Us
CASI is a NASDAQ-listed biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products. Our goal is to establish a platform for launching medicines in the Greater China market with CASI's experienced China-based regulatory and commercial competencies and proficient global drug development expertise.
Learn More
An innovative biopharmaceutical company focused on unmet medical needs
What We Do
Portfolio

Dedicate to hematologic malignancies & oncology

Products

In August 2019, CASI launched EVOMELA® in China as its first commercial product
Pipeline

We have a strong and growing pipeline of commercially available and clinical-staged drug candidates and continue to acquire assets at commercial and/or clinical development stages through in-license and acquisitions
Clinical trials

Explore CASI's clinical trials
Partnering

CASI welcomes partnership opportunities with companies and academic/research institutions that are developing innovative therapeutics
Report a side-effect

At CASI we take the safety of our patients seriously

News

Latest press releases, media assets and global media contacts

CASI Pharmaceuticals Reports Development Relating To Its Disputes With Juventas
CASI Pharmaceuticals Reports Development Relating To Its Disputes With Juventas
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Business and Financial Results
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma In China
Learn More
lnvestors

Continues to create value for shareholders and the society

Financial Reports
2023 2022 2021
Careers
Bring together outstanding people
Learn More

CASI Pharmaceuticals © 2023 CASI Pharmaceuticals Inc.
All Rights Reserved.

Quick links
About Portfolio Media Investors Careers Report a Side Effect
Stay Connected
hr@casi.cn Send mail
Contact Us Privacy Terms of User Cookies Sitemap
Powered by Pousion